Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Business Update

Global Pharmaceutical Companies Turn to Wolters Kluwer to Boost Research Automation & Efficiency


In the highly regulated pharmaceutical industry, implementing the latest technologies to help bring medical breakthroughs to market is of critical importance. That is why Wolters Kluwer Health has collaborated with some of the leading pharmaceutical companies to bring intuitive and easy-to-use workflows to the Ovid® research platform.

Scaling up customizable solutions

The pharma and biotech industries rely on obtaining the latest, most comprehensive clinical information to effectively do their jobs. Automation and efficiency are imperative to manage the massive volumes of information within regulatory, clinical writing, medical affairs, pharmacovigilance, health economics and outcomes research, or publications groups. This allows different organizational functions to complete key tasks with speed and accuracy, such as leveraging hard-to-find data to generate study designs, substantiating findings for regulatory agencies, and gathering the latest information regarding disease management.

"Each pharmaceutical, life sciences and biomedical organization must adhere to strict regulatory guidelines, while also having unique needs for their specific business focus. Providing those institutions with an expert solution that is flexible, while continuously supplying authoritative information in a timely and digestible manner, is crucial," said Rafael Sidi, Senior Vice President & General Manager of Health Research, Wolters Kluwer Health. "The Ovid research platform is uniquely positioned to support this industry, empowering researchers by putting essential information from a vast array of trusted resources at their fingertips."

Improving workflow and productivity through understanding researchers' tasks

Ovid medical research solutions enhance search precision and workflow speed to maximize research productivity. Teams improve their efficiency with more focused results, drug-specific keywording, and a clear path to the full text of relevant research. Additionally, the platform helps reduce administrative overhead, by freeing team members to spend more time on stakeholder engagement and regulatory requirements.

Wolters Kluwer worked with the world's top pharmaceutical company to develop new enhancements in the Ovid research platform that will improve research automation and efficiency across the industry. New research tool updates include:

Learn more about the vital role that the Ovid research platform can play for pharma organizations and review this case study on how an international, rare drug manufacturer is currently leveraging the platform's tools to accelerate their research.

For more information about Wolters Kluwer, please visit: www.wolterskluwer.com

About Wolters Kluwer

Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.

Wolters Kluwer reported 2023 annual revenues of ?5.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,400 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, YouTube and Instagram.


These press releases may also interest you

at 04:45
ERS Genomics Limited (?ERS'), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS' CRISPR/Cas9 patent portfolio....

at 03:15
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on haemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary haemostatic gel, VETIGEL®, to be sold directly...

at 02:30
Ahead of International Tea Day - 21st May 2024  - and with summer inspiring more of us to get off the sofa to be active, a 2024 real-world research study1 reviewed by the tea science experts at the Tea Advisory Panel ? www.teaadvisorypanel.com -...

at 02:30
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....



News published on and distributed by: